SequelSEC

Aspire Biopharma Holdings, Inc. ASBP

Pharmaceutical Preparations · CIK 0001847345 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$97.66K
Fiscal year ended 2026-06-30
Operating income
-$7.32M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Aspire Biopharma Holdings, Inc. (ASBP) reported revenue of $97.66K and net income of -$11.05M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aspire Biopharma Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aspire Biopharma Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$97.66K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$7.32M
Net income-$11.05M
Research & development$838.14K
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$6.23M
General & administrative$4.16M
Selling & marketing$2.07M

Balance

Aspire Biopharma Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$12.17M
Total assets$13.54M
Current assets$13.47M
Total liabilities$1.78M
Current liabilities$1.69M
Total equity incl. NCI$11.76M
Temporary (mezzanine) equityUnavailable
Inventory$288.45K
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$972.11K

Cash flow

Aspire Biopharma Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Aspire Biopharma Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-7494.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio7.99x
Revenue YoY growthUnavailable
Net margin-11314.1%
R&D / revenue858.2%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ASBP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K/A · Filed 2026-04-08View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q/A · Filed 2025-11-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.